FDA Approves Seventh Ustekinumab Biosimilar, Steqeyma

Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-approves-seventh-ustekinumab-biosimilar-steqeyma-2024a1000ojd?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost